BRISTOL-MYERS SQUIBB COMPANY Total Assets
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Total Assets of $87.63 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-07-30
- 2026-06-30: Assets $87.63B.
- 2026-03-31: Assets $86.48B.
- 2025-12-31: Assets $90.04B.
- 2025-09-30: Assets $96.89B.
| Period end | Assets |
|---|---|
| 2026-06-30 | $87.63B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $86.48B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $90.04B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $96.89B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $94.68B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $92.43B 10-Q · filed 2025-04-24 |
| 2024-12-31 | $92.60B 10-K · filed 2026-02-11 |
| 2024-09-30 | $93.67B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $94.65B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $99.03B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $95.16B 10-K · filed 2025-02-12 |
| 2023-09-30 | $91.26B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $93.49B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $94.28B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $96.82B 10-K · filed 2024-02-13 |
| 2022-09-30 | $98.20B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $100.36B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $103.03B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $109.31B 10-K · filed 2023-02-14 |
| 2021-09-30 | $110.89B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $110.80B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $112.44B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $118.48B 10-K · filed 2022-02-09 |
| 2020-09-30 | $125.54B 10-K · filed 2021-02-10 |
| 2020-06-30 | $128.08B 10-K · filed 2021-02-10 |
| 2020-03-31 | $129.28B 10-K · filed 2021-02-10 |
| 2019-12-31 | $129.94B 10-K · filed 2021-02-10 |
| 2019-09-30 | $57.43B 10-K · filed 2021-02-10 |
| 2019-06-30 | $55.16B 10-K · filed 2021-02-10 |
| 2019-03-31 | $34.83B 10-K · filed 2021-02-10 |
| 2018-12-31 | $34.99B 10-K · filed 2020-02-24 |
| 2018-09-30 | $33.73B 10-K · filed 2020-02-24 |
| 2018-06-30 | $32.64B 10-K · filed 2020-02-24 |
| 2018-03-31 | $33.08B 10-K · filed 2020-02-24 |
| 2017-12-31 | $33.55B 10-K · filed 2019-02-25 |
| 2017-09-30 | $33.98B 10-K · filed 2019-02-25 |
| 2017-06-30 | $33.41B 10-K · filed 2019-02-25 |
| 2017-03-31 | $32.94B 10-K · filed 2019-02-25 |
| 2016-12-31 | $33.71B 10-K · filed 2018-02-13 |
| 2016-09-30 | $33.73B 10-K · filed 2018-02-13 |
| 2016-06-30 | $32.83B 10-K · filed 2018-02-13 |
| 2016-03-31 | $31.89B 10-K · filed 2018-02-13 |
| 2015-12-31 | $31.75B 10-K · filed 2017-02-21 |
| 2015-09-30 | $31.78B 10-K · filed 2017-02-21 |
| 2015-06-30 | $31.95B 10-K · filed 2017-02-21 |
| 2015-03-31 | $33.58B 10-K · filed 2017-02-21 |
| 2014-12-31 | $33.75B 10-K · filed 2016-02-12 |
| 2014-09-30 | $33.45B 10-K · filed 2016-02-12 |
| 2014-06-30 | $33.50B 10-K · filed 2016-02-12 |
| 2014-03-31 | $33.42B 10-K · filed 2016-02-12 |
| 2013-12-31 | $38.59B 10-K · filed 2015-02-13 |
| 2013-09-30 | $36.80B 10-K · filed 2015-02-13 |
| 2013-06-30 | $36.25B 10-K · filed 2015-02-13 |
| 2013-03-31 | $35.96B 10-K · filed 2015-02-13 |
| 2012-12-31 | $35.90B 10-K · filed 2014-02-14 |
| 2012-09-30 | $36.04B 10-K · filed 2014-02-14 |
| 2012-06-30 | $31.67B 10-K · filed 2014-02-14 |
| 2012-03-31 | $32.41B 10-K · filed 2014-02-14 |
| 2011-12-31 | $32.97B 10-K · filed 2013-02-15 |
| 2011-09-30 | $32.01B 10-K · filed 2013-02-15 |
| 2011-06-30 | $31.83B 10-K · filed 2013-02-15 |
| 2011-03-31 | $30.85B 10-K · filed 2013-02-15 |
| 2010-12-31 | $31.08B 10-K · filed 2012-02-17 |
| 2010-09-30 | $31.89B 10-Q · filed 2010-10-26 |
| 2010-06-30 | $31.05B 10-Q · filed 2010-07-22 |
| 2010-03-31 | $30.75B 10-Q · filed 2010-04-29 |
| 2009-12-31 | $31.01B 10-K · filed 2011-02-18 |
| 2009-09-30 | $30.95B 10-Q · filed 2009-10-22 |
| 2009-06-30 | $29.81B 10-Q · filed 2009-07-23 |
| 2008-12-31 | $29.49B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |